TransIT®-Oligo Transfection Reagent

A high efficiency, low toxicity, transfection reagent optimized for oligonucleotide delivery into a wide range of cell types

To inquire about bulk pricing, please call 888-530-0801
International inquiries please call +1-608-441-2852
Return Policy

Select a Size:

MIR 21640.4 mlMIR 21601 mlMIR 21655 x 1 mlMIR 216610 x 1 ml

Catalog number selected: -

-

Generate a Quote
  • Unique Formulation – Maximize transfection performance of oligonucleotides into a wide range of cells
  • Low Cellular Toxicity – Maintain cell density and reduce experimental biases
  • High Efficiency Delivery – Achieve high transfection efficiency in cells to ensure experimental success

Oligonucleotides tested:
phosphodiester DNA, phosphothioate DNA (sDNA), phosphothioate RNA (sRNA), 2'OMe RNA, 2'OMe RNA/sDNA Chimerics, Morpholino/DNA duplexes, siRNA and miRNA.

Mirus recommends TriLink BioTechnologies, Inc. for a variety of modified and custom oligonucleotides. Learn more by clicking on their logo below.
trilink logo

Figures and Data

Copy Link Enlarge Image
TransIT-Oligo Reagent Achieves High Transfection Efficiency

TransIT®-Oligo Reagent Achieves High Transfection Efficiency. HeLa cells transfected using TransIT®-Oligo Reagent and Label IT® Cy®3 and Label IT® Fluorescein labeled phosphothioate DNA oligos in complete media for 24 hours.

Copy Link Enlarge Image
TransIT-Oligo Reagent Effectively Transfects a 2'OMe RNA Oligo that Blocks a Cryptic Splice Site

TransIT®-Oligo Reagent Effectively Transfects a 2'OMe RNA Oligo that Blocks a Cryptic Splice Site. The HeLa-Luc 705 reporter cell line (Kang et al. 1998, 37:6235) used in this study contains a luciferase reporter construct that has the ß-globin 705 intron inserted into the luciferase ORF. A mutation present at position 705 of the ß-globin intron activates two cryptic splice sites within the intron that lead to the production of a spliced luciferase mRNA that is disrupted by a small intron with an in-frame stop codon, thus preventing translation of functional luciferase protein. The transfection of a 2'OMe oligonucleotide (TriLink BioTechnologies, Inc.) complementary to the cryptic 705 splice site inhibits splicing at the cryptic splice sites enabling the complete removal of the ß-globin intron and production of a mRNA with a complete, uninterrupted luciferase ORF.

The HeLa-Luc 705 cell line was transfected with increasing amounts of the anti-705 splice site 2'OMe RNA oligo at the indicated final concentrations using the TransIT®-Oligo Transfection Reagent. The cells were harvested 24 hours post-transfection and assayed for luciferase activity. The increase in luciferase activity indicates effective delivery of the anti-705 splice site RNA oligo using the TransIT®-Oligo Reagent.

Resources

Specifications

Storage Conditions:
All Configurations: Store at 4°C

Product Guarantee:
All Configurations: 1 year

Usage Statement:
All Configurations: For Research Use Only.

Technical Product Literature


Additional Resources

COA Lookup

Download Certificates of Analysis

COO Lookup

Download Certificate of Origin

Testimonials

Excellent technical support, they are very knowledgeable.
He Song Sun
University of Toronto Scarborough - Cell and Molecular Biology